Answers are grounded in this paper and cite their sources.
Stem cell therapy for diabetes is moving from basic research to clinical validation, bringing new hope for a curative strategy. This article systematically reviews the core progress and challenges in this field. Diabetes is fundamentally characterized by the failure of pancreatic β-cell function, and current therapies cannot reverse the disease course. Stem cells, due to their self-renewal and differentiation potential, have become a key candidate for replacing damaged β-cells. Embryonic stem cells and induced pluripotent stem cells can generate insulin-secreting cells through directed the differentiation, among which the embryonic stem cell route has entered clinical trials and has obtained evidence of functional cure; induced pluripotent stem cells are suitable for individualized treatment, but are hindered by safety and efficiency issues. Mesenchymal stem cells improve the pancreatic microenvironment through immunomodulation and paracrine effects. Multiple meta-analyses have shown that they can significantly reduce glycated hemoglobin and reduce insulin dosage and have good safety. In 2026, a Chinese team reported a study on regenerating islets, which was the first to achieve islet function reconstruction in humans and obtained approval for new drug clinical trials in China and the United States, marking a key step in clinical transformation. However, immune rejection, tumor risk, production standardization, and insufficient long-term efficacy evidence remain major obstacles. In the future, it is necessary to leverage gene editing, metabolic reprogramming, and multi-omics technologies to promote the implementation of individualized and standardized treatment plans and ultimately achieve functional cure of the diabetes.
No takes yet. Share an insight, caveat, or question.
Ziwen Wang (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: